Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Nihon Chouzai to Open More Stores Filling Prescriptions from Wide Range of Med Institutions
June 6, 2011
- Pfizer Japan Signs Comprehensive Agreement with NCC for Clinical Trials of Anticancer Drugs
June 6, 2011
- Kantar Health Highlights Crizotinib
June 6, 2011
- R&I Downgrades Takeda Following Announcement of Acquisition of Nycomed
June 6, 2011
- Nippon Zoki, Teikoku Seiyaku to Codevelop Adhesive Agent for PHN
June 6, 2011
- Daiichi Sankyo Aims for Sales of ¥40 Bil. in China
June 6, 2011
- HPV Vaccine Gardasil Recommended for Approval
June 6, 2011
- ¥45.5 Billion Worth of New-type Flu Vaccines Discarded: Health Minister Hosokawa
June 6, 2011
- PIII Clinical Trial of Lu AA21004 for MDD Starts in Japan: Takeda
May 30, 2011
- Otsuka Announces 1st Midterm Management Plan
May 30, 2011
- BI, Eli Lilly Obtain Approval for Linagliptin in US
May 30, 2011
- Takara Bio Aims for Sales of \22.7 Bil. in FY2013
May 30, 2011
- Terumo Starts Domestic Clinical Study of Acetaminophen
May 30, 2011
- Mediceo: Yakkasa Reduction Rate of Just 0.5 Points in FY2010
May 30, 2011
- Sales Up 5.6% for Ethical Drugs in March Following Disaster: Crecon Research & Consulting
May 30, 2011
- Wholesale Business Deteriorating due to War for Market Share: Mr Hamada of Toho HD
May 30, 2011
- Teva to Acquire Majority Stake in Taiyo
May 30, 2011
- Premium for New Drug Development an “Incentive”to Japan Business: Chairman Viehbacher of PhRMA
May 30, 2011
- Teva-Taiyo Strategic Tie-up to Have “No Major Impact”on Sawai: President Sawai
May 30, 2011
- Astellas Completes Acquisition of Perseid
May 30, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…